We have a Her-Vaxx Pipeline

All of a sudden we have a Her-Vaxx pipeline. Of course it never happens that way in biotech as each step involves months or years of work. The publication of the pipeline for Her-Vaxx, however, is yet another positive affirmation that the current phase 1b trial in gastric cancer is expected to yield encouraging results. Its moved beyond a wait-and-see to lets aggressively plan ahead - PIPELINE.


The IST or combination study in breast cancer is the most advanced and possibly the most exciting given that it involves the combination of Her-Vaxx and Herceptin. The modelling for the IST will be dependent in large part upon the current study data. In fact the IST will be initiated upon the announcement of the RP2D or Recommended Phase 2 dose. The RP2D is one of the key endpoints of the Phase 1b trial.

Vaccines are back in vogue. It will be interesting to see the nature of the support for the IST including the calibre of the members of the investigation team which already includes Christoph Zieliniski. The investigational use of Herceptin by Imugene as a sponsor, raises all kinds of interesting questions. Typically, it can involve the provision of funding, drug product or both.